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Abstract
The First International Scientific Conference on Human Endogenous Retroviruses (HERVs) and Disease, Lyon-France,
May 26-27th 2015, brought together scientific and medical specialists from around the world investigating the
involvement of human endogenous retroviruses (HERVs) in complex human diseases.
Introduction
The objective of this meeting was to increase awareness
on emerging perspectives in this research area, which
remains vibrant despite much debate and controversy
over the past few decades. This meeting afforded a first
opportunity to focus on the potential impact of these
elements on pathological pathways leading to chronic,
multifactorial and still incurable human diseases. The
first steps toward innovative therapeutic developments
arising from dedicated research on HERVs were also
presented.
Attempts to identify among environmental viruses, a
causative agent of autoimmunity, of chronic inflammation
and of specific tissue lesions involving either immunological
and physiological impairments as in Multiple Sclerosis
(MS) or type 1 Diabetes (T1D), or neurodevelopmental and
neurobiological abnormalities as in Schizophrenia (SZ) or
bipolar disorder (BD), or particular neurodegenerative pro-
cesses as in amyotrophic lateral sclerosis (ALS), have con-
sistently failed. Such diseases are now considered to have a
multifactorial etiology leading to complex pathophysiology
and to chronic-relapsing or progressive evolution. They are
most often thought to result from gene-environment inter-
actions, in particular host susceptibility genes with infec-
tious agents. Human genome studies have investigated
DNA sequences in exons encoding somatic proteins or
their associated regulatory sequences and, apart from few
monogenic and inherited diseases, have generated a global
vision of variable panels consisting in multiple susceptibility
genes thought to cause a disease when associated. Environ-
mental infections likely act as co-factors or triggers for the
etiopathogenesis of the disease, but not as direct causative
agents as in classical infectious diseases.
Since the 1980’s, a new horizon in the search for patho-
genic players in complex human disease arose from stud-
ies in human cells obtained from patients with cancer or
with chronic neuroinflammatory disease such as MS, in
which human endogenous retrovirus (HERV) multicopy
families were identified from elements expressed in associ-
ation with reverse-transcriptase activity and/or virion-like
particles. These observations were initially regarded as
anecdotal but, as studies further explored and progres-
sively unveiled unexpected genetic and biological features
of these HERVs in association with different diseases
during the past decades, it became apparent that HERVs
(as other mobile genetic elements) were not merely fossils
of past infection and inert relics of ancient genomic
invasions, but could display activities with a substantial
impact on cellular function, in both health and disease
(References of review articles available from correspond-
ing author).
Endogenous retroviruses and their relatives are cur-
rently known to occupy approximately 8 % of the human
genome, are separated into diverse multicopy families
and are also part of the broader category of “mobile
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genetic elements”, which together account for at least half
of the human genome. Cumulated results from numerous
studies on HERVs and related elements over the past
30 years, the number of which increased exponentially
since the early years of the 21st century, brought conver-
ging and consistent observations in different disciplines as
in different complex diseases. They now provide a global
picture suggesting that environmental infectious agents
may play a role in triggering the expression of certain
HERVs with selective tropism for permissive cell pheno-
types cells, which in turn may express products (RNA or
protein) or cause genetic modifications, thereby engaging
pathogenic pathways leading to final pathognomonic
features of certain complex diseases.
These scientific advances along with the first therapeutic
developments targeting HERV-W envelope protein in MS
and, as now envisaged, HERV-K in ALS, are now provid-
ing a new perspective of the “gene-environment interplay”
underlying the etiopathogenesis of certain complex hu-
man diseases. This prompted different groups and organi-
zations involved in research and/or development in this
novel but rapidly emerging domain to instigate an inter-
national conference gathering both basic and clinical
scientists from various disciplines (genetics/genomics,
immunology, virology, cell biology, etc.…) in order to
share and debate current and future research on “HERV
and Disease” within a multidisciplinary and transversal
approach.
This international workshop on Human Endogenous Ret-
roviruses and Diseases, “HERV & Disease”, was held 26–
27th May 2015 in Lyon, France. The organizing committee
consisted in: Hervé Perron (Geneuro-Innovation), Patrice
Marche (INSERM), François Curtin (Geneuro) and Jean-
Louis Touraine (University of Lyon). The workshop drew
over a hundred attendees who actively participated in scien-
tific exchanges and debates. Invited presentations ranged
from the general biology of HERVs in the context of human
genome evolution to the role of endogenous retroviruses in
animal disease. The workshop included 5 scientific sessions:
Neurological diseases, Virus interplay with HERV patho-
geny, Neuropsychiatric diseases, Diabetes and Cancer.
Here, we present highlights from the talks from all sessions.
Of note, a considerable fraction of the data presented
at the workshop and reported in this article (with the
consent of the authors) remains, to this date, unpub-
lished and should be considered and treated as such and
therefore not cited in other publications. Published
scientific and clinical studies or reviews could not be
cited in this report but references can be obtained from
authors.
Keynote addresses
Cédric Feschotte (Department of Human Genetics, Uni-
versity of Utah School of Medicine, Salt Lake City, UT,
USA) opened the meeting with a keynote address enti-
tled: “Of Good and Evil: Biological Impact of Endogen-
ous Retroviruses and Other Invasive Genetic Elements”.
He explained how the genomes of various eukaryotes
are replete with viral sequences that are integrated or
'endogenized' in chromosomes and how recent studies
have revealed that virtually all types of viruses can be
endogenized. He emphasized that retroviruses are by far
the best-characterized and most common source of
endogenous viral elements in mammalian genomes,
accounting for 6-14 % of mammalian genome thus far
sequenced, and that their pervasive infiltration is a sub-
stantial source of genetic variation across and within
species. He presented an overview of several well docu-
mented instances where specific ERV have influenced,
for better or worse, the evolutionary trajectory of their
host species. More specifically, he presented recent
evidence obtained in his laboratory that ERVs have been
co-opted during mammalian evolution to rewire a tran-
scriptional network orchestrating the interferon re-
sponse, a crucial arm of innate immunity. These data
shed new light on the mechanisms by which misregula-
tion of ERVs may promote disease states, such as auto-
immunity and tumorigenesis.
Frédérick Arnaud (UMR754, Université Claude Bernard
Lyon 1/Institut National de la Recherche Agronomique/
Ecole Pratique des Hautes Etudes, Lyon, France) opened
the second day with a keynote address entitled: “Friendly
viruses: antiviral activities of ERVs against the oncogenic
Jaagsiekte sheep retrovirus”.
He presented an original mechanism by which certain
animal ERVs could confer protection to their host
against a related pathogenic retrovirus, here Jaagsiekte
sheep retrovirus(JSRV). JSRV is the causative agent of
ovine pulmonary adenocarcinoma and coexists with re-
lated endogenous retroviruses (enJSRVs) that colonized
the sheep genome throughout evolution. He explained
how collaborative studies with Barbara Viginier and
Christophe Terzian’s group in Lyon (University of Lyon),
as well as with Alessia Armezzani and Massimo Palmari-
ni’s group (MRC Centre for Virus Research University of
Glasgow; Glasgow, Scotland) led to discover that two
enJSRV proviruses (enJS56A1 and enJSRV-20), which
separately entered the host genome within the last 3
million years, acquired a defective Gag polyprotein
resulting in a transdominant phenotype able to block
late replication steps of related JSRV. He showed how
these two “protective” proviruses became fixed and amp-
lified in the genome of domestic sheep supporting the
idea of their positive selection during, or immediately
before, sheep domestication (9,000 years ago). He further
presented how they also identified a recent provirus
(<200 years old) with an intact genomic organization
that escapes the restriction induced by enJS56A1 and
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enJSRV-20. He concluded that the invasion of the sheep
genome by endogenous retroviruses is still ongoing and
has not reached an equilibrium yet. He made the audi-
ence aware of how sheep thereby provide an exciting
model to study the co-evolution between ERVs and their
host and to understand how ERV copies may confer
resistance to a disease by interfering with related patho-
genic retroviruses.
The first session, which represented most advanced
studies and developments in the field of diseases associ-
ated with HERVs, took all day on May 26th, after
welcome and introductory talks by Jean-Louis Touraine
and Hervé Perron followed by the keynote lecture by
Cédric Feschotte.
Session 1: Neurological diseases and HERVs
Avi Nath (Section of infections of the Nervous System,
National Institute of Neurological Diseases and Stroke,
National Institutes of Health, Bethesda, Maryland, USA)
reviewed consistent and independent studies that have
shown an activation and upregulation of HERV-K in
patients with amyotrophic lateral sclerosis (ALS). ALS is
a devastating neurodegenerative disease for which there
is no treatment available. Genetic mutations have been
identified in nearly 20 % patients but the remaining are
sporadic cases. He presented the work from his labora-
tory showing that all major transcripts of HERV-K were
expressed in the frontal cortex of nearly 50 % patients
with ALS at autopsy. He showed confirmation by quan-
titative polymerase chain reaction for the pol, gag and
env genes and by immunostaining with an antibody to
the env protein, of specific expression in cortical neu-
rons and anterior horn cells of the spinal cord in pa-
tients with ALS but not in controls. His data from in
vitro and in vivo studies indicated that HERV-K enve-
lope protein displayed neurotoxicity for motor neurons,
suggesting a pathogenic role in ALS. He concluded on a
therapeutic rationale for targeting HERV-K in ALS.
Hervé Perron reminded how the first observation of
retrovirus-like particles with reverse transcriptase activ-
ity was made in leptomeningeal cells shed in the cere-
brospinal fluid of a patient with progressive MS in the
late 1980’s. Similar observations in macrophage cultures
versus controls and in EBV-transformed MS B-cells by
the same and another independent group were simultan-
eously published in The Lancet (1991). He explained
how the molecular identification of this “MS-associated”
retrovirus (MSRV) RNA was achieved from purified
virions in collaboration with Jeremy Garson (UCL,
London, GB), as published in the Proceedings of the
Academy of Sciences of the USA (1997), how sequences
of a complete retroviral genome were further obtained by
PCR extension with this material and, using MSRV-
derived probes, how they unravelled the HERV-W family.
He outlined that this novel human retrovirus did not cor-
respond to an HTLV-like retrovirus, as suggested by
Hilary Koprowski, Robert Gallo and colleagues in a study
published in Nature (1985), but to HERVs that were still
considered as “junk DNA”. He presented how following
studies addressed the question whether this expression
was a trivial activation of harmless HERV elements or
whether this could be involved in MS pathogenesis. HP
described the different independent confirmations that
have now depicted a central pathogenic role of HERV-W
envelope protein (MSRV-Env or HERV-W/Env) in the
initiation and lifelong holding of MS pathogenesis. He also
summarized parallel studies that showed how HERV-W
activation and its envelope protein suggested a common
pathogenic pathway in several other neuroinflammatory
or autoimmune diseases. He gave an overview of the key
aspects that were elucidated and allowed to bridge this
original discovery to the clinical relevance and to an in-
novative therapeutic development as presented by other
speakers during this session. HP concluded that, taken
altogether, the present data now suggest that HERV
elements could be missing links between environmental
factors and complex human diseases, in which the patho-
genesis has no etiological explanation. Thus, such “dor-
mant retroviruses awaken” have been designated as “the
enemy within” in recent publications and may constitute a
new category of pathogens, different from classical envir-
onmental and infectious microbes, since arising from the
host’s genome itself.
Patrick Küry (University of Düsseldorf, Germany)
demonstrated that the envelope protein of HERV-W
(MSRV-Env) affects differentiation of oligodendroglial
precursor cells (OPCs), which normally remyelinate cen-
tral nervous system lesions. He showed that macro-
phages/microglia in MS brain lesions express HERV-W/
Env on the cell surface and can be found in close prox-
imity to OPCs. Presented data showed that either
recombinant protein or cells expressing HERV-W/Env
prevented OPC maturation into oligodendrocytes and
production of myelin proteins. This was shown to be
mediated by MSRV-Env interaction with TLR4 and to
induce nitrosative stress in OPCs. PK argued that data
supported a direct role of HERV-W/Env in the remyeli-
nation blockade of MS lesions. He furthermore showed
that this pathogenic effect was reverted by a humanized
neutralizing antibody targeting MSRV-Env, thus provid-
ing perspectives of therapeutic application restoring the
remyelinating potential of OPCs in MS.
Patrice Marche (U823 INSERM-University of Grenoble,
France) showed that the HERV-W envelope protein (MSRV
type) has specific and wide effects on brain endothelial cells
with implicit consequences on the blood–brain barrier
(BBB) integrity and on interactions with immune lymphoid
cells. He detailed how this is again mediated by targeted
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activation of TLR4 pathways and, when exposed to MSRV-
Env, how human brain cells (HCMEC/D3 line) or human
vascular endothelial cells (HUVEC) upregulate expression
of ICAM-1 integrin leading to an increased adhesion of
lymphocytes to endothelial cell, followed by transmigration
of lymphocytes across the endothelial barrier. These pro-
inflammatory properties were observed with MSRV type
HERV-W envelope but not with its HERV-W analog,
Syncytin. PM reviewed recently published data from his
group supporting the hypothesis that, through TLR4 path-
ways, MSRV-Env affects several cell types (e.g. endothelial
cells, macrophages, B lymphocytes…) contributing to the
immune infiltration of the brain through BBB in the patho-
genesis of MS.
Antonina Dolei (Department of Biomedical Sciences,
University of Sassari, Italy) discussed why immuno-
pathogenic phenomena leading to MS could be triggered
by an environmental factor operating on a predisposing
genetic background. She argued that the consistent stud-
ies involved the Epstein Barr virus (EBV), and the
HERV-W family including the MSRV element, able to
form extracellular virions, and Syncytin-1, the envelope
product of the ERVW-1 gene from an HERV-W copy on
chromosome 7q21-22 with mutated and inactive gag
and pol genes preventing virion production. AD pre-
sented studies from her group with repeated observa-
tions of extracellular MSRV particles, MSRV-specific
mRNA sequences in MS blood, spinal fluid (CSF) or
brain samples, and MRSV load paralleling MS stages,
activity and therapy outcome. She detailed a long-term
follow-up study, in which early MSRV detection of in
CSF predicted the worst MS progression, more than ten
years in advance. She further presented in vitro studies
of HERV-W expression in blood and brain cells exposed
to EBV or to EBV glycoprotein350: in vitro, EBV acti-
vated the HERV-W/MSRV envelope protein; HERV-W/
MSRV activation is higher in blood cells of patients with
infectious mononucleosis and in healthy controls with
high anti-EBNA-1 IgG titers. AD concluded from these
data and from the literature on MS pathogenesis that
EBV could be an initial trigger of a risk for MS and that
MSRV could have a direct role of effector of neurotox-
icity and immunoinflammation during MS.
Jack Van Horssen (Department of biochemistry and
Molecular immunology, VU-University Amsterdam, The
Netherlands) presented the results of his immunohisto-
chemical study, which showed HERV-W Env and GAG
protein distribution and cellular localization in different
stages of MS lesion development in a large cohort of
well-characterized MS samples. He presented how
HERV-W Env and GAG proteins are abundantly present
in demyelinated areas with ongoing inflammation and,
at the cellular level, in infiltrated macrophages as well as
in activated microglia. JvH showed a moderate HERV-W
Env/GAG-immunodetection in astrocytes throughout
active and chronic active lesions but, within chronic in-
active lesions only in few HERV-W Env-immunoreactive
astrocytes. He concluded that this extensive immunohis-
tochemical survey revealed that both HERV-W Env and
HERV-W GAG protein expression is markedly upregu-
lated in inflammatory MS lesions and, in microglia, is
associated with areas of active demyelination.
John Kriesel presented results from his group having
used deep sequencing to identify viral RNA signatures in
human brain specimens. He explained how they had
previously used this method to detect HSV1, GBV-C,
and measles virus sequence in brain tissue from de-
ceased patients. Deep sequencing was performed on
brain specimens from a cohort of patients with progres-
sive MS, revealing increased expression of HERV do-
mains. Sequence comparisons revealed many differences
for several HERV domains. After corrections for mul-
tiple tests, 2 GAGs and one KRBA sequence were
significantly enriched in MS samples compared to con-
trols. Average HRs were calculated for each domain type
– AP (protease), GAG, ENV, INT, RT, and KRAB. JK
presented a dendrogram constructed from hierarchical
clustering that was used to discriminate MS and controls
and 16 different candidate GAG and ENV domains over-
expressed in MS sample have been selected for follow
up RT-qPCR. He concluded that such data demonstrate
that HERV and KRAB domains are significantly overrep-
resented in brain tissue specimens from cooresponding
series, which supports the hypothesis that expression of
endogenous retroviral sequences parallels MS pathogen-
esis, potentially reconciling the autoimmune and infec-
tious nature of this challenging disease.
Ranjan Dutta (Department of Neurosciences, Cleve-
land Clinic, Cleveland, OH, USA) presented results from
a recently started collaboration with the Neurology
department in Düsseldorf, Germany (David Kremer and
Patrick Küry). This study focused on cellular sources of
HERV-W/Env expression in primary or secondary pro-
gressive MS (PPMS, SPMS) brains. At the beginning of
his presentation RD reminded the audience that a cure
for MS awaits the discovery of its underlying cause,
though two known factors contribute to MS: a genetic
predisposition and environmental agents. While few
genes associated with MS susceptibility are described,
limited research directly focuses on causes such as infec-
tious agents. MS research traditionally focused on white
matter demyelination although there is significant de-
myelination of the cortex. Demyelination happens with-
out significant infiltration of lymphoid cells whereas
recent studies suggest that cortical demyelination may
exceed white matter demyelination. RD explained that a
major challenge is therefore to determine how gray mat-
ter demyelination occurs. He then showed dystrophic
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oligodendrocytes in affected cortical regions with three-
dimensional electron microscopic (3D-EM) analysis of
postmortem MS brains, in which he identified proteins
and organelles accumulation, whereas large scale viral
sequencing analysis identified reads matching with the
human endogenous retrovirus W (HERV-W) in MS
brains with myelin loss. Immunostaining of demyeli-
nated primary progressive MS cortical brain tissue with
an anti-HERV-W/ENV antibody revealed its cellular
localization in perivascular cuffs, within the parenchymal
extracellular space, and in a microglial subpopulation.
These cells also expressed HERV-W/Env receptor
(TLR4) and were in direct contact with axons. RD con-
cluded that ENV might play a role in the proinflamma-
tory activation of microglia, thus contributing to myelin
and axonal degeneration in progressive MS– a hypoth-
esis currently under functional evaluation in both part-
ner laboratories.
Guilherme Sciascia do Olival (Emilio Ribas Infectology
Institute Neuroscience and CATEM – Multiple Sclerosis
Center of Santa Casa of São Paulo, São Paulo, SP, Brazil)
presented results from a collaboration with Camila
Malta Romano (Luiz Henrique da Silva Nali, Augusto
Cesar Penalva de Oliveira) along with the group of Neu-
rosciencies of Emilio Ribas Institute (São Paulo, SP,
Brazil). He presented results on HERV-W expression in
MS patients under different treatments and disease stage
with next generation sequencing analysis of the HERV-
W transcripts estimating potential active loci in MS and
healthy conditions and an ongoing project ERV tran-
scriptome analysis. GSdO presented preliminary data
using HERV-W envelope amplicon deep sequencing
methodology on blood samples collected from 4 MS pa-
tients in relapse, from 6 MS patients with different treat-
ments (Natalizumab and immunossupressors) and from
5 healthy subjects. He explained that the most repre-
sented transcripts in MS matched with chromosomes 1,
6, 9, 14 and X. Transcripts from healthy subjects, with
lower expression, matched with chromosomes 1, 6, 7
and 14. He presented results from MS in relapse that
showed elevated transcription matching with about 16
known loci but that healthy individuals presented only
detectable expression matching with nine loci (p = 0.01).
GSdO noticed no difference between transcription levels
of patients undergoing treatments with Natalizumab and
β-Interferon, compared to untreated MS cases in relapse.
Interestingly, patients with high EDSS (>6) had much
wider transcript sequence diversity, which consequently
“matched” many more loci than patients with low EDSS
(<3). He debated that this sequence diversity cannot cor-
respond to known genomic loci, which would be in line
with reported increase of HERV-W DNA copy numbers
in PBMC from such patients with elevated EDSS and/or
disease activity in studies by Garcia-Montojo et al.
(Madrid, Spain), Perron et al. (Geneva, Switzerland) and
Mameli et al. (Sassari, Italy). He concluded that HERV-
W envelope expression is different between MS patients
and healthy controls but that patients with high EDSS or
those in relapsing conditions have more heterogeneous
expression, possibly also underlying relationship between
HERV-W and autoimmunity in MS.
Alain Créange (Université Paris 12 and Groupe Hospi-
talier Henri Mondor, Créteil, France) presented the asso-
ciation between chronic inflammatory demyelinating
polyneuropathy (CIDP), an acquired immune-mediated
inflammatory disorder of the peripheral nervous system
(PNS), and HERV-W/MSRV envelope protein expres-
sion. He presented a collaborative study with the
Lausanne University Hospital (CHUV-Switzerland) and
GeNeuro. Env antigenaemia in CIDP patients was de-
tected in 24/49 cases (49 %) whereas 3/18 (17 %) healthy
controls were positive, which reached statistical signifi-
cance (p < 0.01). Low levels of Env positivity (4/20) were
observed with other neurological diseases (e.g., spastic
paraparesis, metabolic neuropathies and Parkinson's dis-
ease). qRT-PCR results on peripheral blood mono-
nuclear cells as well those of immunostaining on nerve
biopsies corroborated these data. Since CIDP shares
common features with MS pathogenesis, this strongly
suggests that similar pro-inflammatory processes are
elicited by HERV-W envelope in peripheral nerve. Such
a possible involvement in CIDP might open novel per-
spectives for the development of targeted therapeutic
approaches.
Raphaël Faucard (Geneuro-Innovation, France), pre-
sented data about Env mediated TLR4 signaling and
peripheral nerve myelinating glial cells - Schwann cells -
upon exposure to HERV-W Env protein. A pharmaco-
logical characterization of Env and GNbAC1, the neu-
tralizing therapeutic antibody specifically targeting Env,
was carried out using human (h)TLR4 overexpression by
HEK-BlueTM cells. This analysis confirmed that a) Env is
a highly potent full agonist of recombinant hTLR4, b) its
effects are inhibited by GNbAC1 in a concentration
dependent manner and c) Env effect is mediated by its
direct binding to hTLR4. It was then reported that two
highly selective TLR4 inhibitors have been identified:
LPS-RS as competitive ENV antagonist and Cli-095 as
another signaling antagonist. RF thus argued that this
was the first complete pharmacological profiling of a
biological response associated to an HERV element. He
further presented effects on Schwann cells exposed to
Env, either transfected with or stimulated by MSRV-Env,
which produced high levels of interleukin-6 (IL-6) and
of chemokine CXCL10, two key immune mediators
involved in CIDP pathology. He showed that effects cor-
related glial TLR4 expression and were inhibited by
GNbAC1. He concluded that the HERV-W impact in
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PNS pathologies might exceed inflammation and could
also include crosstalk between immune- and Schwann
cells.
Alexander Emmer (Neurology department, University
Hospital, Halle, Germany) then presented a recently
published concept on the role and functionality of super-
antigens. His group previously demonstrated that T cell
superantigens such as Staphylococcal enterotoxin A
(SEA) can induce inflammatory reactions in different
organs such as CNS, joints and muscles of experimental
animals. He explained that inflammatory processes in-
duced by the same superantigen (SEA) differed between
the affected organs but mimicked corresponding human
autoimmune diseases. Superantigen dependent induction
of inflammation revealed independent from adjuvant
mediated bypass of immune tolerance. AM showed that
many autoimmune diseases display oligoclonal immuno-
globulin bands in cerebrospinal fluid or different types
of serum autoantibodies in other autoimmune diseases.
He showed that B-cell superantigens such as gp120 (part
of the HIV-envelope) can activate blood lymphocytes in
vitro to produce immunoglobulin in an oligoclonal man-
ner. Finally, he mentioned that another prominent fea-
ture of autoimmune diseases is organ degeneration. In
many instances organ degeneration is only attributed to
inflammation, however, it is important to state that de-
generation may also develop in the absence of apparent
major inflammation, as seen in progressive MS. He con-
cluded that that HERV-W pathological effects may also
occur in the absence of inflammation, indicating that
HERV-W mode of action may also be independent of its
superantigenic power.
Finally, François Curtin, the CEO of the GeNeuro gave
an update on the clinical development of HERV-W Env
neutralizing antibodies; following the identification of
precursor murine and chimeric antibody versions,
GNbAC1, a humanized IgG4 mAb, emerged from pre-
clinical studies aiming at blocking HERV-W Env protein
in MS patients. In an initial phase I trial GNbAC1 was
well tolerated and only minor or nonspecific adverse
events (AEs) occurred. A dose-linear pharmacokinetic
profile was revealed and no anti-GNbAC1 antibodies
were detected in any subject over the entire observation
period of 64 days. He presented the follow up phase IIa
randomised clinical study over one year, with ten MS
patients randomized into two cohorts receiving an initial
intravenous infusion of GNbAC1/placebo at doses of 2
or 6 mg/kg, followed by five infusions of GNbAC1 at 2
or 6 mg/kg at four-week intervals. He reported that all
patients completed the 6-Months study, which was
extended to one year with same regimen. Again,
GNbAC1 pharmacokinetics were dose-linear, no anti-
GNbAC1 antibodies were detected and no evidence of
adverse effects was observed. FC highlighted that HERV-
W transcripts decreased during the treatment and that
nine patients had stable brain lesions at MRI (one
dropped before final MRI analysis). He concluded that
GNbAC1 could be a safe long-term treatment for MS
patients, with promising hypothesis to be challenged in
the upcoming phase IIb clinical trial.
Introducing the next sessions, which took place during
the second day, Frédérick Arnaud (Lyon, Fr. and Glasgow,
UK) highlighted the complex interplay between the
Jaagsiekte sheep retrovirus (JSRV), causative agent of
ovine pulmonary adenocarcinoma, and the highly related
endogenous retroviruses (enJSRVs). These enJSRV copies
not only play a critical role in conceptus development and
placental morphogenesis of sheep, but can also block
JSRV replication at early and late stages of the retroviral
cycle (Cf. Keynote presentations).
Session 2: Virus interplay with HERV pathogeny
The group of Elena Uleri (Department of Biomedical
Sciences, University of Sassari, It.) showed that HIV tat
encoded protein activates HERV-W/MSRV/Syncytin-1
in cells from blood and brain through Tat interaction
with TLR4 and induction of TNF-α. In vivo translation
suggest that Tat may promote neuroinvasion by HIV-
infected macrophages, eliciting neuroinflammation and
neuropathogenicity related to HERV-W elements. It was
concluded that HERV-W neuropathogenic potential
could contribute to NeuroAIDS pathogenesis.
Benjamin Charvet (International Centre for Infectiology
Research, INSERM U1111/CNRS UMR5308/Ecole Nor-
male Supérieure de Lyon/University of Lyon, France)
analyzed the interactions between the HHV-6A herpes-
virus and HERV-W, showing specific HERV-W env over-
expression in HHV-6A infected glial cells, and confirming
previous data of HHV-6A-induced over-expression of
HERV-K18 env in lymphoid cells. He showed that HERV-
W env does not involve the CD46 receptor for HHV-6A
and that inactivated HHV6 virus is not efficient; whereas
infectious HHV-6A induced HERV-W env transactivation
in glial cells. He concluded that, when occurring, an early
activation of HERV-W by HHV-6A may contribute to
initiate neuroinflammatory and cytopathic effects of fur-
ther self-sustained HERV-W envelope expression, thereby
contributing to MS etiology.
Session 3: Neuropsychiatric diseases and HERVs
Håkan Karlsson (Karolinska Institutet, Stockholm, Sweden)
reported the identification of transcripts from HERV-W in
samples from patients with schizophrenia using PCR and
next-generation sequencing. He also showed transcriptional
de-repression of HERV-W loci by virus infection in human
cell-lines. He discussed the potential role of HERV-W as a
marker or mediator of environmental risk factors in
schizophrenia.
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Laurent Groc (CNRS - University of Bordeaux, France)
discussed the potential impact of HERV-W envelope com-
pared to other relevant agonists, on the surface dynamics
of NMDA receptors. He explained that the regulation of
NMDA receptor signaling is highly dependent on the sur-
face diffusion of the receptor and its dynamic anchoring
within postsynaptic densities. He presented demonstration
of a potent link between exposure to HERV-W/Env and
NMDAR surface dynamics. LG emphasized that the pat-
tern of the response was unique to HERV-W/Env com-
pared to all other tested compounds, including LPS
another TLR4 agonist. He concluded discussing the po-
tential impact of HERV-W env expression, beyond its
pro-inflammatory effects, on neuroreceptor dysregulation
as observed in psychoses such as schizophrenia and bipo-
lar disorder.
Pierre Ellul (University of Créteil, Fondation fonda-
Mental and APHP, France) reviewed the literature on
HERV expression in schizophrenia and other psychoses
and hypothesized that environmental exposure to infec-
tious or pro-inflammatory events during pregnancy
cause disturbances in the epigenetic control of HERV
and other retroelements which predispose to excessive
transcription following secondary exposures during post-
natal life. Such activation was hypothesized to contribute
to the pathogenesis of these disorders.
Emanuela Balestrieri (University of Rome, Italy) dis-
used the possible involvement of HERVs in autism. She
showed distinctive expression profiles of HERV families
in samples from autistic patients and a positive correl-
ation with the severity of the clinical signs of the disease.
EB further presented an animal model, consisting in out-
bred mice prenatally exposed to an inhibitor of the his-
tone deacetylases (valproic acid), in which the offspring
of treated mice a dysregulation in the expression of
several different murine retroelements along with behav-
ioural abnormalities, resembling those observed in indi-
viduals with autism.
Session 4: Diabetes and HERVs
Marion Schneider (University of Ulm, Germany) recalled
that type 2 diabetes (T2DM) now affects more than 387
million people worldwide with a global prevalence of
8.3 % and an estimation of about 50 % undiagnosed
cases. T2DM is regarded as an important co-morbidity
in depression or certain psychotic illnesses and is also
one of the major risk factors for patients with major
trauma to proceed into severe sepsis and septic shock in
an intensive care environment. She thereafter presented
her studies on patients with T2DM with sepsis focusing
on peripheral blood phenotyping and highlighted the
increase of non-classically activated macrophages (CD14
+/C16+) in T2DM patients. MS reported how these acti-
vated cells can be enriched in vitro and phenotypically
characterized. She explained that they consist in Imma-
ture dendritic cells (CD14-/CD16+), resembling slanDCs
and M1 (STAT-1 activated), M2a-M2d macrophages and
that cells from sepsis patients with and without T2DM
were studied in her group. She showed that relative
amounts of M1 and M2a macrophages and also slanDCs
with active P2X7 ion channel activities were higher in
T2DM septic patients, compared to non-diabetic patients
with sepsis. She showed that cultures from T2DM patients
significantly expressed s HERV-W env positive cells with
simultaneous HLA-DR downregulation. She also reported
that the ATP-sensitive, inflammasome-related calcium
channel, P2X7 appears to be crucial for HERV-W Env
positive microparticle release. The physiopathological
significance of this increased occurrence of non-classically
activated macrophages and of immature DC (CD14+/C16+;
CD14-/CD16+) in T2DM along with the biological
consequence of associated HERV-W envelope-positive mi-
croparticles release, which may eventually fuse with target
cells in organs and tissue, was discussed. She concluded
that both Type 1 Diabetes and T2DM with sepsis show an
important link of NF-κB and STAT1 activation promoting
iDC and M1 macrophage polarization, resulting in cyto-
toxic and inflammatory functions that may also promote
HERV-W env protein expression.
Julie Medina (Geneuro-Innovation, Lyon, France) recalled
that type 1 diabetes (T1D) is a severe autoimmune disease
characterized by a depletion of insulin-producing beta-cells
in the pancreas, that subjects with T1D are usually
dependent on insulin injections for their entire life and that
T1D accounts for 5 to 10 % of total number of diabetes
cases, Europe having the highest incidence, with peak rates
in Finland and Sardinia. She explained that both genetic
factors and environmental triggers, and viruses in particu-
lar, are supposed to contribute to its etiopathogeny. After
which, she explained how a study on type 1 diabetes (T1D)
arose from MS preclinical study, in which serum samples
from other autoimmune diseases were tested for the pres-
ence MSRV-Env antigen: no significant detection was
found in, e.g., patients with Systemic Lupus (SLE) or
Rhumatoid Arthritis, but was positive in sera of about 40 %
of T1D with variable disease duration. JM explained how
evaluating an eventual involvement of HERV-W in the
pathogeny of T1D, firstly focused on HERV-W/Env expres-
sion in human pancreas biopsies from patients with and
without T1D provided by the nPOD biobank (Univeristy of
Florida, USA) using immunohistochemistry (IHC). She
presented results showing the presence of HERV-W/Env in
T1D biopsies, mainly appearing to be produced by acinar
cells surrounding Langerhans islets. She further presented
in vitro effects of HERV-W/Env on insulin secretion when
tested on cultured insulinoma cell line, which induced a
progressive decrease in insulin secretion. In presence of the
neutralizing antibody specific for HERV-W Env protein a
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normal response to glucose stimulation was restored at any
of the HERV-W Env concentrations studied. Finally, she
presented results showing in vivo effects of HERV-W Env
in a humanized NOD-SCID mouse model, showing that
HERV-W Env leads to hyperglycemia and hypoinsulinemia
but not in presence the monoclonal anti-HERV-W Env
antibody when injected to mice at least one day after
HERV-W/Env. She concluded on the present consistency
between early results from human pancreatic IHC, in vitro
and in vitro models, suggesting that HERV-W could be
involved in T1D pathogeny. She nonetheless commented
that these preliminary results call for further investigation
on larger cohorts that, if in line with present observations,
may provide perspectives for novel therapeutic avenues in
T1D.
Session 5: Cancer and HERVs
François Mallet (Joint Unit Hospices Civils de Lyon-
bioMérieux, Lyon, France) illustrated, using high density
HERV custom microarrays in Affymetrix format and a
panel of 40 normal and tumor epithelial tissue pairs, that
groups of transcriptionally active elements of the HER-
Vome are sensitive to the state of cell differentiation and
follow stringent tropism rules. He exemplified such tis-
sue specificity with results of qRT-PCR follow-up of five
HERV-H elements, initially identified with the HERV
microarray in colon cancer, in a larger cohort of 212
patients; samples comprised adenomas, colorectal car-
cinomas and liver metastasis, normal and tumoral liver
tissue, as well as organs with common sites of metasta-
sis. FM showed that HERV-H expression was maintained
throughout disease progression and strongly correlated
with microsatellite instability in colon cancer.
Reiner Strick (University Clinic Erlangen, Erlangen,
Germany) proposed a candidate/functional gene approach
to decipher HERV expression by immunohistochemistry
or q-PCR in 135 brain tumors consisting of pituitary
adenomas (PA) subtypes as well as of glioblastoma multi-
forme (GBM) and giant cell GBM as compared to normal
adenohypophysis and cortex. He presented Syncytin-1
and 20 ERV functional envelopes expression study and
reported highly up-regulated Syncytin-1, Syncytin-2, erv-3
and envK in different PA subtypes, GBM and giant cell
GBM. RS concluded that HERV genes play an essential
role in PA and GBM, possibly via general cAMP signaling,
where Syncytin-1 could be one main factor contributing
to the multinucleated cells in giant cell GBM.
Claudia Matteucci (University of Roma, Roma, Italy) pre-
sented results on the potential role of HERV-K activation
in cellular plasticity and stemness features of melanoma
cells upon the modification of the microenvironment, recal-
ling that her group previously demonstrated that HERV-K
was associated to aggressiveness and immune evasion of
metastatic melanoma using stress culture conditions. CM
showed that combination of flow cytometry, RT-PCR
analyses, RNA interference, sphere-forming and migration/
invasion assays, using the highly heterogenic human melan-
oma cell line TVM-A12 and other commercial cell lines,
confirmed that melanoma cell plasticity and generation of
CD133+ putative cancer stem cell subpopulation are
HERV-K dependent. She concluded on a promising obser-
vation showing that TVM-A12-CD133+ cells were affected
by non-nucleoside reverse transcriptase inhibitors.
Martin Sebastian Staege (Martin Luther University,
Halle-Wittenberg, Germany) presented his studies on
HERV expression in Hodgkin’s lymphoma (HL) cells,
combining conventional DNA microarray analysis for
the characterization of gene expression in HL cells com-
pared to normal blood cells with in silico identification
of HERV located in the vicinity of expressed genes and
with wet lab experiments on switching mechanism at 5'
end of RNA transcript to validate new HERV-defined
alternative transcription start sites. He concluded that
data obtained by his group indicated that HERV can
recruit alternative promoters in HL cells.
Concluding remarks
This first iteration of the ‘HERV & Disease’ workshop
provided the opportunity to bring together scientists and
clinicians with diverse expertise to share data and ideas
about the biology of HERVs and the possible impact of
these elements in health and disease. The event came
more than two decades after the discovery of the first
HERV-W element isolated from an MS patient, a finding
that has been the subject of much controversy and
debate in the community. How could viral elements as-
similated within the genome of humans trigger diseases
in certain patients but not others? Many laboratories
have invested a considerable effort to clarify this issue,
yielding important clues acting at different levels. First,
recent advances in genomics have started to provide
solutions to the technical challenges posed by the gen-
etic complexity and repetitive nature of HERVs in the
human genome. This is best illustrated with HERV-K
insertions, a growing number of which have now been
shown to be polymorphic and to occur at low frequency
in the human population. Furthermore, at the gene-
environment interface, there is growing recognition of
cross-talks between diverse infectious agents (including
non-retroviral viruses) and HERVs and of their interfer-
ence with inflammatory and cytopathic signaling path-
ways. This particular role of environmental microbes
provides examples of etiopathogenic mechanisms by
which non-physiological HERV activation may occur
and may have biological effects. This would confer a “hit
and run” role for the many infectious factors often but
partially associated with these diseases and a central role
for HERVs that, once transcriptionally activated, can
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trigger and fuel downstream pathogenic cascades leading
to specific lesions or cellular dysfunctions. In parallel,
diseases associated with the activation of elements of the
HERV-W family have now been extended from MS to
other inflammatory neurological or neuropsychiatric dis-
eases, at least one other autoimmune disease (T1D) and,
partly or in association with other HERVs, in some can-
cer states. In the case of HERV-K, evidence is mounting
for the involvement of the HERV-K envelope protein in
the etiopathogenesis of sporadic SLA, which represents
a potential breakthrough for our understanding of this
and other neurodegenerative diseases. So, this and many
other studies on HERVs open exciting prospects as well
as new challenges to elucidate multifactorial etiopatho-
genic pathways and cellular mechanisms underlying the
etiology and progression of many poorly understood
pathologies. There is great hope that innovative therap-
ies will emerge from this research. In this respect, the
good results from early clinical trials (Phase I in healthy
volunteers and Phase IIa in MS patients) for the first
specific immunotherapy targeting an associated patho-
genic HERV protein (references of publications available
from the corresponding author), provide encouraging
and new perspectives for the patients.
The initiative of such an international meeting on
‘HERV & Disease’ is expected to continue. Information
about a new iteration of this workshop will be available
on the website of the meeting before the end of 2015.
Also note that abstracts are freely available online:
www.hervanddisease.com
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